TherapeuticsMD Inc
TXMD1.080USD
-0.030-2.70%
Close 04/23, 16:00（ET）Quotes delayed by 15 min
12.45MMarket Cap
LossP/E TTM
More Details of TherapeuticsMD Inc Company
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
Company Info
Company codeTXMD
Company nameTherapeuticsMD Inc
IPO dateJan 31, 2001
Founded at2010
CEOMr. Marlan D. Walker, J.D.
Number of employees1
Security typeOrdinary Share
Fiscal year-endJan 31
Address951 Yamato Road, Suite 220
CityBOCA RATON
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code33431
Phone15619611900
Websitehttps://www.therapeuticsmd.com/
Company codeTXMD
IPO dateJan 31, 2001
Founded at2010
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Marlan D. Walker, J.D.
Mr. Marlan D. Walker, J.D.
Chief Executive Officer
Chief Executive Officer
73.64K
+3.94%
Mr. Cooper C. Collins
Mr. Cooper C. Collins
Independent Director
Independent Director
60.52K
+16.34%
Dr. Gail K. Naughton, Ph.D.
Dr. Gail K. Naughton, Ph.D.
Independent Director
Independent Director
8.50K
--
Mr. Justin Roberts
Mr. Justin Roberts
Independent Director
Independent Director
--
--
Gov. Thomas G. (Tommy) Thompson, J.D.
Gov. Thomas G. (Tommy) Thompson, J.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Joseph Ziegler
Mr. Joseph Ziegler
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
--
-100.00%
Name
Name/Position
Position
Shareholding
Change
Mr. Marlan D. Walker, J.D.
Mr. Marlan D. Walker, J.D.
Chief Executive Officer
Chief Executive Officer
73.64K
+3.94%
Mr. Cooper C. Collins
Mr. Cooper C. Collins
Independent Director
Independent Director
60.52K
+16.34%
Dr. Gail K. Naughton, Ph.D.
Dr. Gail K. Naughton, Ph.D.
Independent Director
Independent Director
8.50K
--
Mr. Justin Roberts
Mr. Justin Roberts
Independent Director
Independent Director
--
--
Gov. Thomas G. (Tommy) Thompson, J.D.
Gov. Thomas G. (Tommy) Thompson, J.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Joseph Ziegler
Mr. Joseph Ziegler
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
--
-100.00%
Revenue Breakdown
Currency: USDUpdate time: Wed, Mar 5
Currency: USDUpdate time: Wed, Mar 5
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Mayne Pharma
68.56M
98.00%
Theramex
1.40M
2.00%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Mayne Pharma
68.56M
98.00%
Theramex
1.40M
2.00%
Shareholder
Update time: Sun, Feb 23
Update time: Sun, Feb 23
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Rubric Capital Management LP
10.30%
Clearline Capital LP
5.49%
Tejara Capital Ltd.
3.41%
The Vanguard Group, Inc.
3.35%
Adar1 Capital Management LLC
2.33%
Other
75.12%
Shareholder Statistics
Shareholder
Proportion
Rubric Capital Management LP
10.30%
Clearline Capital LP
5.49%
Tejara Capital Ltd.
3.41%
The Vanguard Group, Inc.
3.35%
Adar1 Capital Management LLC
2.33%
Other
75.12%
Type
Shareholder
Proportion
Hedge Fund
19.63%
Investment Advisor/Hedge Fund
4.88%
Investment Advisor
4.82%
Individual Investor
2.02%
Research Firm
1.15%
Other
67.49%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
89
3.76M
32.49%
-1.84M
2024Q4
95
3.73M
32.32%
-2.03M
2024Q3
99
3.59M
31.15%
-463.34K
2024Q2
121
3.62M
31.37%
-2.25M
2024Q1
209
3.66M
32.13%
-802.21K
2023Q4
230
4.54M
44.12%
-1.60M
2023Q3
274
4.44M
43.31%
-158.22K
2023Q2
299
4.48M
44.55%
-545.84K
2023Q1
319
4.85M
52.06%
-356.05K
2022Q4
333
5.71M
62.28%
+1.23M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Rubric Capital Management LP
1.19M
10.3%
-1.75M
-59.54%
Dec 31, 2024
Clearline Capital LP
635.22K
5.49%
-1.40K
-0.22%
Dec 31, 2024
Tejara Capital Ltd.
394.66K
3.41%
-6.79K
-1.69%
Dec 31, 2024
The Vanguard Group, Inc.
387.58K
3.35%
--
--
Dec 31, 2024
Adar1 Capital Management LLC
270.16K
2.33%
--
--
Dec 31, 2024
Citadel Advisors LLC
145.80K
1.26%
+145.80K
--
Dec 31, 2024
Morgan Stanley & Co. LLC
130.44K
1.13%
-3.00
-0.00%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
116.13K
1%
--
--
Dec 31, 2024
Geode Capital Management, L.L.C.
108.33K
0.94%
--
--
Dec 31, 2024
Walker (Marlan D)
70.85K
0.61%
+8.28K
+13.24%
Feb 18, 2025
View more
Related ETFs
Update time: Sun, Apr 6
Update time: Sun, Apr 6
Name
Proportion
Schwab U.S. Small-Cap ETF
0%
Schwab U.S. Broad Market ETF
0%
iShares Micro-Cap ETF
0%
Schwab U.S. Small-Cap ETF
Proportion0%
Schwab U.S. Broad Market ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 06, 2022
Merger
50<1
May 06, 2022
Merger
50<1
May 06, 2022
Merger
50<1
May 06, 2022
Merger
50<1
Date
Type
Ratio
May 06, 2022
Merger
50<1
May 06, 2022
Merger
50<1
May 06, 2022
Merger
50<1
May 06, 2022
Merger
50<1